A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence.

BACKGROUND AND PURPOSE: Locally recurrent rectal cancer (LRRC) is associated with considerable morbidity, poor quality of life and an overall survival of 9 months. The non-operative treatment of LRRC is an understudied area, there is no consensus on management in this setting. We aim to perform a retrospective, multicentre analysis of patients treated with SABR reirradiation. MATERIALS AND METHODS: All patients were identified who received SABR re-irradiation for LRRC, at 3 UK centres, between August 2015 and September 2020. Eligible patients had pelvic recurrence and were either not suitable/opted not for surgery, or margin positive after exenturative surgery. Patients were treated with 30 Gy in 5 fractions and followed up with clinical review and CT scan at 3, 6, 12, 18 and 24 months. RESULTS: 69 patients with 81 lesions were identified and median follow up was 28 months. Median progression free survival (PFS) and overall survival (OS) were 12.1 months (10.4, 17.7) and 38.7 months (28.9,-) respectively. 2-year OS was 0.77 (0.66, 0.89). 58.3% of deaths were as a result of consequences of local relapse. 42.6% of patients had local relapse at death or last follow up. CONCLUSION: Our outcomes are encouraging for a population who had R1 resections, refused or were refused surgery; as they are similar to those in surgical series. Prospective data including details of survival, local relapse and QOL; with an optimised SABR technique, is required to establish SABR as an alternative to surgery.

Considerations for future novel human-infecting coronavirus outbreaks.

Up until, June 13, 2020, >7,500,000 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and >400,000 deaths, across 216 countries, have been confirmed by the World Health Organization (WHO). With reference to the two previous beta-CoV outbreaks (SARS-CoV and middle east respiratory syndrome [MERS]), this paper examines the pathophysiological and clinical similarities seen across all three CoVs, with a special interest in the neuroinvasive capability and subsequent consequences for patients with primary or metastatic brain tumors. More widely, we examine the lessons learned from the management of such large-scale crises in the past, specifically looking at the South Korean experience of MERS and the subsequent shift in disaster management response to SARS-CoV-2, based on prior knowledge gained. We assess the strategies with which infection prevention and control can, or perhaps should, be implemented to best contain the spread of such viruses in the event of a further likely outbreak in the future.

Pembrolizumab-associated autoimmune haemolytic anaemia.

Treatment paradigms have recently changed with the introduction of immunotherapy; autoimmune toxicities that can arise are frequently very different from the more familiar chemotherapy toxicities. We present a clinical case of autoimmune haemolytic anaemia (AIHA) secondary to pembrolizumab occurring in a 73-year-old male patient being treated for lung adenocarcinoma, who had received 13 cycles of pembrolizumab. Treatment was immediately stopped and he was treated with high dose steroids to which he responded both clinically and biochemically. There have been prior reports of immunotherapy-associated AIHA with the use of cytotoxic T-lymphocyte-associated antigen-4 inhibitors, such as ipilimumab, but very few reports of programmed death-1 (PD-1)/programmed death-ligand 1 (PDL-1) inhibitor associated AIHA. We highlight a rare case of AIHA as an adverse effect of pembrolizumab, a PD-1 inhibitor. Although unusual, it is important to be vigilant for haematological immune-related adverse events.

A challenging case of concurrent multiple sclerosis and anaplastic astrocytoma.

BACKGROUND: Cases of gliomas coexisting with multiple sclerosis (MS) have been described over the past few decades. However, due to the complex clinical and radiological traits inherent to both entities, this concurrent phenomenon remains difficult to diagnose. Much has been debated about whether this coexistence is incidental or mirrors a poorly understood neoplastic phenomenon engaging glial cells in the regions of demyelination. CASE DESCRIPTION: We present the case of a 41-year-old patient diagnosed with a left-sided frontal contrast enhancing lesion initially assessed as a tumefactive MS. Despite systemic treatment, the patient gradually developed signs of mass effect, which led to decompressive surgery. The initial microscopic evaluation demonstrated the presence of MS and oligodendroglioma; the postoperative evolution proved complex due to a series of MS-relapses and tumor recurrence. An ulterior revaluation of the samples for the purpose of this report showed an MS-concurrent anaplastic astrocytoma. We describe all relevant clinical aspects of this case and review the medical literature for possible causal mechanisms. CONCLUSION: Although cases of concurrent glioma and MS remain rare, we present a case illustrating this phenomenon and explore a number of theories behind a potential causal relationship.

Pituitary carcinomas: Rare and challenging.

BACKGROUND: Pituitary carcinomas (PCs) are defined as adenohypophyseal tumors with metastatic activity within and outside the boundaries of the central nervous system (CNS). The condition is rare and therefore seldom reported; most lesions are hormone producing and have a tendency for complex evolution. As such, the management of PCs remains difficult. We present an illustrative case of PC with a brief review of the recent medical literature. CASE DESCRIPTION: A 58-year-old patient was diagnosed with prolactinoma in 2005. The ensuing biochemical and radiological evolution proved contentious; local tumor control was never fully achieved despite multimodal management including pharmacological treatment, repeated resections, and radiotherapy. In late 2017, the patient developed metastatic lesions within the confinements of the CNS requiring further surgical interventions, high-dose radiation, and systemic treatment. CONCLUSION: As it was the case in our patient, PCs require tailored, multimodal treatments according to the degree of infiltration, site of invasion, and hormone status. Further studies are necessary to understand the mechanisms promoting "extra-sellar" activity, particularly at distant sites; the identification of biomarkers exposing the risk of PC remains a crucial aspect of diagnostics, prevention and future customized therapies.

Successful application of keratinocyte suspension using autologous fibrin spray.

OBJECTIVE: The back is a challenging anatomical area to resurface in acute burns due to its large surface area, its dependent position with the patient lying down and the shearing forces applied to any method of resurfacing employed. This case study presents the use of Vivostat® (Vivostat A/S, Lillerød, Denmark) in resurfacing the back in conjunction with Recell® regenerative epithelial suspension. Vivostat® (Vivostat A/S, Lillerød, Denmark) is a "novel patented biotechnological process that enables reproducible preparation of autologous fibrin sealant or platelet rich fibrin without cryoprecipitation or a separate thrombin component" [1]. METHODS: A 29-year-old female sustained 27% total body surface area (TBSA) flame burns, including the whole back. This area was initially grafted with the sandwich autograft/allograft technique on day four after injury, with approximately 80% graft take on day eight. Unfortunately, there was subsequent significant graft loss on the back proving to be a stubborn area to treat despite further grafting sessions. This challenge led to the decision to use Vivostat® (Vivostat A/S, Lillerød, Denmark) and Recell® to resurface the back. RESULTS: The patient underwent one session of resurfacing with Vivostat® (Vivostat A/S, Lillerød, Denmark) and Recell® and went on to have full healing on the back. CONCLUSIONS: NICE (The National Institute for Health and Care Excellence) states that Recell® shows potential to improve healing in acute burns and we believe that its co-delivery with fibrin via Vivostat® (Vivostat A/S, Lillerød, Denmark) allows for precise delivery of the fibrin suspended cells while minimising loss in the "run off" encountered when Recell® is just simply sprayed on, assisting the anchoring of keratinocytes to the wound surface and thus aiding in the treatment of challenging areas.

Prevention of dehydration in hospital inpatients.

BACKGROUND: The adverse effects of dehydration in hospital inpatients can be severe, resulting in morbidity and even mortality. This study examined the ability of surgical patients in a district general hospital to undertake the seemingly minor but critically important task of taking on oral fluids using the conventional, hospital-supplied, water jug and glass. METHODS: Surgical patients receiving oral fluids were interviewed on two occasions. A questionnaire assessed the patient's capacity to use the water jug and recorded his or her experience. The patient's ability to use jugs with varying volumes of water was then observed. RESULTS: Some patients simply could not physically lift the conventional jug of water and often went thirsty; 42% of patients could not reach the jug of water at the time of interview; 31% of patients found the simple task of pouring a glass of water difficult, very difficult or impossible. CONCLUSION: Patients need their individual requirements to be assessed and their preferences addressed on admission to hospital, by means of a fluid-assessment chart. Alternative methods of hydration should also be considered. Education and training on the importance of hydration remain key. These small changes could improve patient hydration and independence, thus preventing avoidable harm.